JP2023526348A5 - - Google Patents
Info
- Publication number
- JP2023526348A5 JP2023526348A5 JP2022570127A JP2022570127A JP2023526348A5 JP 2023526348 A5 JP2023526348 A5 JP 2023526348A5 JP 2022570127 A JP2022570127 A JP 2022570127A JP 2022570127 A JP2022570127 A JP 2022570127A JP 2023526348 A5 JP2023526348 A5 JP 2023526348A5
- Authority
- JP
- Japan
- Prior art keywords
- viral vector
- viral
- cell line
- producing
- accessory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063025812P | 2020-05-15 | 2020-05-15 | |
| US63/025,812 | 2020-05-15 | ||
| PCT/US2021/032479 WO2021231884A1 (en) | 2020-05-15 | 2021-05-14 | Compositions and methods for producing stable viral vector producer cells for cell and gene therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526348A JP2023526348A (ja) | 2023-06-21 |
| JP2023526348A5 true JP2023526348A5 (enExample) | 2024-05-22 |
Family
ID=76306023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570127A Pending JP2023526348A (ja) | 2020-05-15 | 2021-05-14 | 細胞療法及び遺伝子療法のための安定したウイルスベクター産生細胞を産生するための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220154215A1 (enExample) |
| EP (1) | EP4150097A1 (enExample) |
| JP (1) | JP2023526348A (enExample) |
| KR (1) | KR20230017799A (enExample) |
| CA (1) | CA3183599A1 (enExample) |
| WO (1) | WO2021231884A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12357704B2 (en) | 2019-05-06 | 2025-07-15 | Thomas Malcolm | Tailored hypoimmune nanovesicular delivery systems for cancer tumors |
| US12054738B2 (en) | 2020-07-30 | 2024-08-06 | Shape Therapeutics Inc. | Stable cell lines for inducible production of rAAV virions |
| JP2024537896A (ja) | 2021-10-18 | 2024-10-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞 |
| AR127674A1 (es) | 2021-10-18 | 2024-02-21 | Regeneron Pharma | Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios |
| WO2023230230A1 (en) * | 2022-05-25 | 2023-11-30 | Malcolm Thomas | Tailored hypoimmunogenic biomimetic nanovesicle delivery system for viral infection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981276A (en) | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| CA2344208A1 (en) * | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Method |
| WO2013076309A1 (en) * | 2011-11-24 | 2013-05-30 | Genethon | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
| DK3294893T5 (da) * | 2015-05-13 | 2024-10-07 | Csl Behring Gene Therapy Inc | Bioproduktion af lentivirale vektorer |
| FR3044016A1 (fr) * | 2015-11-24 | 2017-05-26 | Glaxosmithkline Ip Dev Ltd | Lignees cellulaires stables pour la production retrovirale |
| GB201706121D0 (en) * | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Stable cell lines for retroviral production |
| JP7470119B2 (ja) * | 2018-08-24 | 2024-04-17 | シーエスエル ベーリング ジーン セラピー インコーポレイテッド | 無血清培地におけるベクター産生 |
-
2021
- 2021-05-14 KR KR1020227043618A patent/KR20230017799A/ko active Pending
- 2021-05-14 EP EP21730742.0A patent/EP4150097A1/en not_active Withdrawn
- 2021-05-14 WO PCT/US2021/032479 patent/WO2021231884A1/en not_active Ceased
- 2021-05-14 CA CA3183599A patent/CA3183599A1/en active Pending
- 2021-05-14 JP JP2022570127A patent/JP2023526348A/ja active Pending
-
2022
- 2022-01-31 US US17/589,840 patent/US20220154215A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102423444B1 (ko) | 레트로바이러스 벡터 | |
| RU2752498C2 (ru) | Стабильные клеточные линии для продуцирования ретровирусов | |
| AU2022218478B2 (en) | Bio-production of lentiviral vectors | |
| JP3864049B2 (ja) | ウイルスコード配列を含有していない高い効率を有するレトロウイルスベクター | |
| KR20130101527A (ko) | 렌티바이러스 벡터의 안정한 제조 | |
| Kiem et al. | Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo | |
| Adamson et al. | Approaches to maximize sgRNA-barcode coupling in Perturb-seq screens | |
| JP2023552663A (ja) | 安定したレンチウイルスパッケージング細胞株およびその作成方法 | |
| EP4304618A1 (en) | Compositions and methods for producing and characterizing viral vector producer cells for cell and gene therapy | |
| JP6878620B2 (ja) | レトロウイルス産生のための安定な細胞株 | |
| Santhosh et al. | A lentiviral vector with novel multiple cloning sites: stable transgene expression in vitro and in vivo | |
| AU2021206846B2 (en) | Lentivirus packaging system, method for improving lentivirus production in a host cell, and method for treating cancer | |
| Kim et al. | Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain | |
| Jespersen et al. | Expression of heterologous genes from an IRES translational cassette in replication competent murine leukemia virus vectors | |
| US9840720B2 (en) | Materials and methods relating to packaging cell lines | |
| US20110008894A1 (en) | Lyophilized plasmid/dna transfection reagent carrier complex | |
| Reil et al. | CD4 expressing human 293 cells as a tool for studies in HIV-1 replication: the efficiency of translational frameshifting is not altered by HIV-1 infection | |
| CN113832191B (zh) | 慢病毒载体、系统及其应用 | |
| KR20240024807A (ko) | 렌티바이러스 벡터 | |
| CN115247190A (zh) | 慢病毒包装系统、其所制得的慢病毒及经该慢病毒转导的细胞及其应用 | |
| JP4482639B2 (ja) | レンチウイルスベクターに対する効率的なパッケージング細胞を産生するための選択システム | |
| Miklík et al. | Long Terminal Repeats of Gammaretroviruses Retain Stable Expression After Integration Retargeting or Knock-In into the Restrictive Chromatin of Lamina-Associated Domains | |
| KR102704463B1 (ko) | 렌티바이러스를 이용한 차세대 시퀀싱 기반 재조합 단백질 발현을 위한 세포 내 고발현 영역 탐색 방법 및 고발현 영역 정보 | |
| LLC | Development and Optimization of a High Titer Recombinant Lentivirus System | |
| Rasmussen et al. | Complementarity between RNA dimerization elements favors formation of functional heterozygous murine leukemia viruses |